Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia


IMPACT FACTOR 2015: 0.742

SCImago Journal Rank (SJR) 2015: 0.204
Source Normalized Impact per Paper (SNIP) 2015: 0.333
Impact per Publication (IPP) 2015: 0.507

Open Access
Online
ISSN
1452-8266
See all formats and pricing

 


Select Volume and Issue

Issues

Recommedition for Apllication and Determination Tumor Markers of Neuroendocrine System

Duško Mirković1

Institute of Medical Biochemistry, Clinical Centre of Serbia and School Pharmacy, University of Belgrade, Belgrade, Serbia1

This content is open access.

Citation Information: Journal of Medical Biochemistry. Volume 26, Issue 2, Pages 157–164, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: https://doi.org/10.2478/v10011-007-0019-3, April 2007

Publication History

Published Online:
2007-04-24

Preporuke Za Primenu I Određivanje Tumorskih Markera Kod Neoplazmi Neuroendokrinog Sistema

Neuroendokrini tumori vode poreklo iz neuroendokrinih ćelija, koji pod uslovima specifične stimulacije sekretuju hormone, regulišući niz različitih funkcija u organizmu. U radu je opisana grupa neuroendokrinih tumora koja se sastoji od: karcinoida endokrinih tumora pankreasa, neuroblastoma, medularnog karcinoma tiroidee i feohromocitoma. Biće diskutovani tumori koji potiču iz endokrinih žlezda, kao i oni koji vode poreklo iz takozvanog »difuznog« neuroendokrinog ćelijskog sistema gastrointestinalnog trakta. Radi se o najvećem endokrinom organu u organizmu. Oko 50 različitih neuroendokrinih ćelijskih tipova gastrointestinalnog trakta je indentifikovano. Važan dijagnostički segment u tretmanu ovih tumora, je određivanje biogenih amina i peptida, čija je aktivnost izmenjena kod pojave neoplazmi. Širok je spektar kliničkih simptoma kod pojave ove vrste tumora, a svi su posledica sposobnosti tumora da sekretuju povećane količine peptinih hormona i biogenih amina. Glavni ciljevi ovog teksta su procena važnosti ove grupe tumorskih markera, kao i predlozi za njihovo koriŠćenje u našim uslovima.

Recommedition for Apllication and Determination Tumor Markers of Neuroendocrine System

Neuroendocrine tumors derive from neuroendocrine cells, which upon specific stimulation secrete stimulation secrete hormones regulating various bodily functions. We will discuss the group of neuroendocrine tumors which is consisted of: carcinoids, endocrine pancreatic tumors, neuroblastomas, medullary thyroid carcinomas and pheochromocytomas. The tumors which derived from endocrine glads will be discused, as well as, we will pay attention on tumors which derived from so called »diffuse« neuroendocrine cell system of the gastrointestinal tract. In fact, this is the largest endocrine organ of the body. About 50 different neuroendocrine cell types of the gastrointestinal tract have been indentified. One of the currently recomended diagnostic approach to these lesions is the determination of characteristic bioactive amines and peptides of neuroendocrine activity, which is changed in neoplasms. The wide spectrum of clinical symptoms are associated with lesions of endocrine glands, and dispersed neuroendocrine system, results from their collective ability to secrete an extensive array of peptide hormones and bioactive amines, that differe according to the tumor type. The main aim of this disscusion is evaluation of these potential tumor markers, and proposing using some of those markers in our conditions.

Keywords: neuroendokrini; tumor; markeri; karcinoid neuroblastom; feohromocitom; karcinom

Keywords: neuroendocrine; markers tumors; carcinoid; neuroblastoma; pheochromocytoma; carcinoma

  • Delellis RA, Tischler AS. Functional Endocrine Pathology. Boston: Blackwell, 1990: 493-508.

  • Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000; 62: 19-26. [Crossref] [PubMed]

  • Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998; 1097-108.

  • Ericson JD, Eiden LE, Schaher MK. Reserpine and tetrabenazine-sensitive transport (3H) - histamine by the neuronal isoform of the vesicular monoamine transport. J Mol Neurosci 1995; 6: 277-87. [Crossref]

  • Feldman J, Moore J. Biogenic amines and carcinoid tumors. Biogenic amines 1989; 6: 247-52.

  • Feldmam JM. Carcinoid Tumors. In: Massaferi EL et al. Endocrine tumors. Boston: Blackwell, 1993; 700-22.

  • Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991; 16: 27-30. [PubMed] [Crossref]

  • Winkler H, Fischer-Colbrie R. The chromogranins A and B; the firs 25 years, and future perspectives. Neuroscience 1992; 49: 497-528. [Crossref]

  • Fischer-Cilbrie R, Frischenschlager T. Immunological characterization of secretory proteins of chromaffin granules: Chromogranin A, chromogranin B, and enkephlin-containing peptides. J Neurochem 1985; 44: 1854-61. [Crossref]

  • Rosa P, Hille A, Lee RHW, Zanini A, Decamilli P, Huttner WB. Secretogranins I II, two tyrosin-sulphated secretory proteins common to a variety of cell-secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999-2011. [Crossref]

  • Fischer-Cilbrie R, Hagn C, Kilpatric L, Winkler H. Chromogranin C: a third component of the acidic proteins in chromaffin granules. J Neurochem 1986; 47: 318-324.

  • Hagn C, Schmid KW, Fisher Colbrie R, Winkler H. Chromatogranin A, B and C in human adrenal medulla and endocrine tissues. Lab Invest 1986; 55: 505-11.

  • Schober M, Fischer-Cilbrie R, Schmid KW, Bussolati G, O'Connor DT Winkler H. Comparsion of chromogranins A, B and secretogranin II in human adrenal medulla and pheochromocytoma. Lab Invest 1987; 57: 385-91.

  • Buffa R, Mare P, Gini A, Salvadore M. Chromogranina A and B and secretogranin II in hormonally identified endocrine cells of the gut and the pancreas. Basic Appl Histochem 1988; 32: 471-84.

  • Hsiao RJ, Mezger MS, O' Connor DT. Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955-64. [PubMed] [Crossref]

  • Stridsberg M, Oberg K, Li Q, Engstrom U, Lidgqist G. Meassurments of chromogranin A, chromogranin B, chromogranin C, and pancreastatin in plasma and urine from patients with carcinoid tumors and endocrine pancreatic tumors. J Endocrinol 1995; 144: 49-59. [Crossref] [PubMed]

  • Williams ED, Sandler M. The classification of carcinoid tumors. Lancet 1963; 1: 238-39. [PubMed] [Crossref]

  • Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumors. World Health Organization international histological classifitacion of tumors. 2nd ed. Berlin: Springer, 2000.

  • Mendonca C, Baptista C, Rames M, Yglesias de Oliveira JA. Typical and atypical loung carcinoids: clinical and morphological diagnosis. Microsc Res Tech 1997; 38: 468-72.

  • Oates J, Sjierdsma A. A unique syndrome associated with secretion of 5-hydroxytryptophan by metastatic gastric carcinoids. Am J Med 1962; 32: 333-42. [Crossref] [PubMed]

  • Norheim I, Wilander E, Oberg K. Tachykinin production by carcinoid tumors in culture. Eur J Cancer Clin Oncol 1987; 23: 689-95. [PubMed] [Crossref]

  • Pernow B, Waldenstrom J, Paroxsysmal flushing and other symtoms caused by 5-hydroxytriptamine and histamine in patients with malignant tumors. Lancet 1954; II: 951.

  • Dusment ME, McKneally MF. Pulmonary and thymic carcinoid tumors. World J Surg 1996; 20: 189-95. [Crossref]

  • Ezzat S, Asa SL, Stefaneanu L, Whittom R, Smyth HS, Horvath E, Kovacs K, Frohman LA. Somatotroph hyperplasia without pitutary adenoma associated with a longstanding growth hormone-realising hormone-producing bronhical carcinoid. J Clin Endocrinol Metab 1994; 78: 555-60. [Crossref]

  • Grouzman E, Fathi M, Gillet M, de Torrente A, Cavadas C, Brunner H, Buclin T. Disappearance rate of catecholamines, total metanephrine, and neuroppeptide Y from the plasma of the patients after resection of pheochromocytoma. Clin Chem 2001; 47: 1075-82.

  • Young WF. Pheochromocytoma. Trends Endocrinol Metab 1993; 4: 122-7. [PubMed] [Crossref]

  • Grahame PE, Smythe GA, Edwards GA. Laboratory diagnosis of pheochromacytoma: which analyte should we measure? Ann Clin Biochem 1993; 30: 129-34.

  • Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340: 1872-79.

  • Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W. Diagnostic efficacy of unconjugated plasma metaneprines for the detection of pheochromocytoma. Arch Intern Med 2000; 160: 2957-63.

  • Grondal S, Eriksson B, Hamberger B, Theodorsson E. Plasma chromogranin A and B, neuropeptide Y and catecholamines in in pheochromacytoma patients. J Intern Med 1991; 229: 453-6.

  • Grouzman E, Gicquel C, Plouin RF, Schlumberger M, Comoy E, Bohuon C. Neuripeptide Y and neuron-specific enolase levels in benign and malignant pheochromacytomas. Cancer 1996; 66: 1833-35.

  • Brodeur GM, Castleberry RP. Principles and and practice of pediatric oncology. Philadelphia: JB Lippinocott, 1993: 739-67.

  • Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma: Serum concentration parallele disease stage and predict survival. J Clin Invest 1990; 85: 1555-9. [Crossref]

  • De Lellis RA, Dayal Y, Tischler AS. Multiple endocrine neoplasia (MEN) syndromes: cellular origins and interrelationships. Int Rev Exp Pathol 1986; 28: 163-215.

  • Boomsma F, Bhagge UM, 't Veld AJMI, Schalekamp MADH. Sensitivity and specifity of a new ELISA method for determination of chromogranine A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 1995; 239: 57-63.

  • Oberg K. Neuroendocrine gastrointestinal tumors: a condesed overview of diagnosis and treatment. Ann Oncol 1999; 10: 3-8. [Crossref]

  • Creutzfeldt W. Insulinomas: Clinical presentation, diagnosis, and advances in management. In: Mignon M, Jensen RT. Endocrine tumors of the pancreas: recent advances in research and management. Basel: Karger, 1995: 148-65.

  • Mignom M, Jais PH, Cadiot G. Clinical features and advances in biological diagnostic criteria for Zollinger-Ellison syndrome. In: Mignon M, Jensen RT. Endocrine tumors of pancreas: recent advances in research management. Basel: Karger, 1995: 223-39.

  • Vinik Al, Strodel WE, Eckhauser FE. Somatostatinomas, pipomas, neurotensinomas. Semin Oncol 1987; 14: 263-81. [PubMed]

  • Long RG, Bryant MG, Mitchell SJ. Clinicopathological study of the pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestnal polypeptide (vipomas). BMJ 1981; 282: 1767-71.

  • Eriksson B, Oberg K. Pipomas, nonfunctioning endocrine pancreatic tumors: clinical presentation, diagnosis and advances in management. In: Mignon M, Jensen RT. Endocrine tumors of pancreas: recent advances in research and management. Basel: Karger, 1995: 208-22.

Comments (0)

Please log in or register to comment.